HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Kazuhiko Nakagawa Selected Research

Topoisomerase I Inhibitors

10/2017DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance.
4/2013Phase II study of bi-weekly irinotecan for patients with previously treated HER2-negative metastatic breast cancer: KMBOG0610B.
7/2010Phase I and pharmacologic study of weekly bolus topotecan for advanced non-small-cell lung cancer.
7/2010Phase II study of sequential triplet chemotherapy, irinotecan and cisplatin followed by amrubicin, in patients with extensive-stage small cell lung cancer: West Japan Thoracic Oncology Group Study 0301.
5/2006A phase I study of irinotecan in combination with amrubicin for advanced lung cancer patients.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Kazuhiko Nakagawa Research Topics

Disease

263Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
09/2022 - 01/2002
173Neoplasms (Cancer)
09/2022 - 01/2002
52Disease Progression
04/2022 - 12/2008
48Lung Neoplasms (Lung Cancer)
09/2022 - 01/2002
24Neutropenia
01/2022 - 01/2003
24Neoplasm Metastasis (Metastasis)
12/2021 - 10/2003
21Stomach Neoplasms (Stomach Cancer)
01/2021 - 05/2003
20Diarrhea
03/2021 - 11/2006
17Colorectal Neoplasms (Colorectal Cancer)
09/2022 - 07/2006
16Breast Neoplasms (Breast Cancer)
01/2022 - 02/2011
16Small Cell Lung Carcinoma (Small Cell Lung Cancer)
05/2020 - 01/2003
16Febrile Neutropenia
01/2020 - 11/2006
15Interstitial Lung Diseases (Interstitial Lung Disease)
01/2022 - 04/2005
13Adenocarcinoma of Lung
03/2021 - 02/2004
11Nausea
01/2021 - 12/2010
11Thrombocytopenia (Thrombopenia)
01/2020 - 01/2003
10Pneumonia (Pneumonitis)
01/2022 - 05/2008
10Fatigue
10/2020 - 06/2009
9Adenocarcinoma
04/2015 - 02/2004
8Pain (Aches)
10/2020 - 08/2011
7Malignant Mesothelioma
06/2021 - 11/2006
7Anemia
01/2020 - 01/2003
7Leukopenia
01/2020 - 01/2003
7Esophageal Neoplasms (Esophageal Cancer)
12/2019 - 11/2005
6Carcinoma (Carcinomatosis)
01/2022 - 02/2008
6Melanoma (Melanoma, Malignant)
01/2021 - 01/2016
6Squamous Cell Carcinoma (Epidermoid Carcinoma)
01/2021 - 02/2004
6Exanthema (Rash)
11/2016 - 02/2009
6Lymphoma (Lymphomas)
03/2015 - 05/2012
5Dermatitis
02/2021 - 11/2017
5Stomatitis
02/2021 - 10/2014
5Paronychia
02/2021 - 10/2014
5Vomiting
01/2021 - 12/2010
5Anorexia
01/2020 - 05/2011
5Fever (Fevers)
12/2019 - 06/2009
5Hypertension (High Blood Pressure)
12/2019 - 09/2010
5Hemorrhage
12/2018 - 02/2012

Drug/Important Bio-Agent (IBA)

81ErbB Receptors (EGF Receptor)IBA
09/2022 - 06/2003
80Tyrosine Kinase InhibitorsIBA
03/2022 - 06/2003
57Gefitinib (Iressa)FDA Link
09/2022 - 06/2003
43Erlotinib Hydrochloride (CP 358,774)FDA Link
01/2022 - 03/2007
34Cisplatin (Platino)FDA LinkGeneric
09/2022 - 03/2002
32Carboplatin (JM8)FDA LinkGeneric
03/2022 - 08/2006
29Docetaxel (Taxotere)FDA Link
09/2022 - 04/2005
27Pharmaceutical PreparationsIBA
01/2022 - 12/2004
24NivolumabIBA
06/2022 - 01/2016
24CrizotinibIBA
01/2021 - 10/2011
22Pemetrexed (MTA)FDA Link
09/2022 - 11/2006
22PlatinumIBA
06/2022 - 04/2004
22Paclitaxel (Taxol)FDA LinkGeneric
01/2022 - 01/2002
21Biomarkers (Surrogate Marker)IBA
04/2022 - 12/2008
20Immune Checkpoint InhibitorsIBA
09/2022 - 01/2016
19Anaplastic Lymphoma KinaseIBA
03/2021 - 04/2011
18osimertinibIBA
04/2022 - 01/2017
17AfatinibIBA
01/2022 - 06/2010
17LigandsIBA
03/2021 - 12/2012
17Alanine Transaminase (SGPT)IBA
03/2021 - 07/2008
16Monoclonal AntibodiesIBA
06/2021 - 08/2009
15Proteins (Proteins, Gene)FDA Link
03/2021 - 01/2004
15Messenger RNA (mRNA)IBA
10/2019 - 02/2004
14Phosphotransferases (Kinase)IBA
01/2021 - 03/2003
13Bevacizumab (Avastin)FDA Link
01/2022 - 04/2012
13GemcitabineFDA Link
12/2021 - 04/2005
13alectinibIBA
01/2021 - 06/2013
13Irinotecan (Camptosar)FDA LinkGeneric
08/2016 - 03/2002
12RamucirumabIBA
01/2022 - 01/2016
11Aspartate Aminotransferases (Aspartate Transaminase)IBA
03/2021 - 11/2011
10Fluorouracil (Carac)FDA LinkGeneric
06/2022 - 06/2007
10pembrolizumabIBA
01/2022 - 01/2016
10dacomitinibIBA
03/2021 - 11/2017
9Cetuximab (Erbitux)FDA Link
01/2021 - 04/2008
9SurvivinIBA
01/2020 - 02/2006
9Neuregulin-1 (Neuregulin 1)IBA
12/2019 - 09/2011
9Microtubule-Associated Proteins (Microtubule-Associated Protein 2)IBA
11/2016 - 04/2011
8nintedanibIBA
03/2022 - 10/2010
8Vinorelbine (Navelbine)FDA LinkGeneric
01/2022 - 08/2006
8Etoposide (VP 16)FDA LinkGeneric
11/2016 - 11/2006
7human ERBB2 proteinIBA
01/2022 - 05/2010
7DNA (Deoxyribonucleic Acid)IBA
01/2021 - 03/2002
7Trastuzumab (Herceptin)FDA Link
01/2019 - 05/2010
6B7-H1 AntigenIBA
12/2021 - 01/2019
6ParaffinIBA
01/2021 - 01/2013
6Formaldehyde (Formol)FDA Link
01/2021 - 01/2013
6Lapatinib (GW572016)FDA Link
08/2018 - 02/2009
6Opioid Analgesics (Opioids)IBA
10/2017 - 12/2011
5Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
01/2021 - 08/2012
5Antineoplastic Agents (Antineoplastics)IBA
12/2020 - 04/2004
5AntibodiesIBA
05/2020 - 01/2012
5sepantroniumIBA
01/2020 - 10/2008
5AnthracyclinesIBA
10/2019 - 01/2010
5patritumabIBA
01/2019 - 12/2014
5EnzymesIBA
10/2018 - 01/2005
5Dasatinib (BMS 354825)FDA Link
11/2017 - 01/2010

Therapy/Procedure

108Therapeutics
01/2022 - 11/2005
101Drug Therapy (Chemotherapy)
09/2022 - 03/2002
28Radiotherapy
12/2021 - 09/2006
13Chemoradiotherapy
06/2021 - 11/2005
12Immunotherapy
01/2022 - 02/2004
10Combination Drug Therapy (Combination Chemotherapy)
01/2021 - 03/2006
7Aftercare (After-Treatment)
01/2021 - 03/2015